US 12,767,719 B2 · CCR8 antibody and application thereof

Abstract

Involved is an isolated antigen binding protein, being capable of binding CCR8 derived from a primate animal. Further involved are a pharmaceutical composition comprising the antigen binding protein, and an application of the antigen binding protein and/or the pharmaceutical composition in the prevention and/or treatment of a tumor or a cancer.

An isolated antigen-binding protein that binds CCR8, comprising an antibody heavy chain or a fragment thereof and an antibody light chain or a fragment thereof, wherein the antibody heavy chain or the fragment thereof comprises an HCDR1, an HCDR2 and an HCDR3, and the antibody light chain or the fragment thereof comprises an LCDR1, an LCDR2 and an LCDR3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprise amino acid sequences selected from any one of the following groups:

(1) LCDR1:
SEQ ID NO:
111, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
22, HCDR2:
SEQ ID NO:
48, and HCDR3:
SEQ ID NO:
80;
(2) LCDR1:
SEQ ID NO:
111, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
22, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
72;
(3) LCDR1:
SEQ ID NO:
111, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
22, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
80;
(4) LCDR1:
SEQ ID NO:
111, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
22, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
81;
(5) LCDR1:
SEQ ID NO:
111, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
22, HCDR2:
SEQ ID NO:
48, and HCDR3:
SEQ ID NO:
81;
(6) LCDR1:
SEQ ID NO:
111, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
22, HCDR2:
SEQ ID NO:
48, and HCDR3:
SEQ ID NO:
82;
(7) LCDR1:
SEQ ID NO:
111, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
22, HCDR2:
SEQ ID NO:
48, and HCDR3:
SEQ ID NO:
83;
(8) LCDR1:
SEQ ID NO:
106, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
16, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
65;
(9) LCDR1:
SEQ ID NO:
105, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
15, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
65;
(10) LCDR1:
SEQ ID NO:
105, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
16, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
65;
(11) LCDR1:
SEQ ID NO:
106, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
15, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
65;
(12) LCDR1:
SEQ ID NO:
106, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
16, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
68;
(13) LCDR1:
SEQ ID NO:
106, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
16, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
72;
(14) LCDR1:
SEQ ID NO:
106, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
16, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
73;
(15) LCDR1:
SEQ ID NO:
106, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
21, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
65;
(16) LCDR1:
SEQ ID NO:
106, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
22, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
65;
(17) LCDR1:
SEQ ID NO:
106, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
22, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
72;
(18) LCDR1:
SEQ ID NO:
106, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
22, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
73;
(19) LCDR1:
SEQ ID NO:
106, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
150;
HCDR1:
SEQ ID NO:
16, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
65;
(20) LCDR1:
SEQ ID NO:
106, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
151;
HCDR1:
SEQ ID NO:
16, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
65;
(21) LCDR1:
SEQ ID NO:
106, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
152;
HCDR1:
SEQ ID NO:
16, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
65;
(22) LCDR1:
SEQ ID NO:
107, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
16, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
65;
(23) LCDR1:
SEQ ID NO:
107, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
16, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
68;
(24) LCDR1:
SEQ ID NO:
111, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
16, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
65;
(25) LCDR1:
SEQ ID NO:
111, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
22, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
73;
and
(26) LCDR1:
SEQ ID NO:
112, LCDR2:
SEQ ID NO:
127, LCDR3:
SEQ ID NO:
142;
HCDR1:
SEQ ID NO:
16, HCDR2:
SEQ ID NO:
38, and HCDR3:
SEQ ID NO:
65.

362 more elements

CCR8 antibody and application thereof

Life of this patent

CCR8 antibody and application thereof

Life of this patent

Abstract

Claims20